ReviewCold Spring Harbor perspectives in medicine2012
Signal transduction by vascular endothelial growth factor receptors.
Review in Cold Spring Harbor perspectives in medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 468 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
468 citing papers in PubMed, 3 syntheses or guidelines pooled it, 882 citations in OpenAlex.
- The safety and efficacy of VEGFR tyrosine kinase inhibitors for patients with gliomas: a systematic review, meta-analysis, and a specific analysis on glioblastoma.Neurosurgical review · 2025Pooled it
- Association of Four VEGFA Gene Variants with Rheumatoid Arthritis Risk: A Meta-analysis and Trial Sequential Analysis.Biochemical genetics · 2025Pooled it
- Intrauterine hCG application increases expression of endothelial cell-cell adhesion molecules in human.Archives of gynecology and obstetrics · 2021Pooled it
- VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.Scientific reports · 2022Trial
- Effect of intersphincteric fistula tract ligation versus anal fistulectomy on pain scores and serum levels of vascular endothelial growth factor and interleukin-2 in patients with simple anal fistulas.The Journal of international medical research · 2020Trial
- Toward precision oncology: deciphering the circRNA-EMT axis in cancer and its therapeutic implications.RNA biology · 2026Review
- VEGFAngiogenesis · 2026Article
- Targeting vascular endothelial growth factor (VEGF)-induced angiogenesis withNutrition research and practice · 2026Article
- Receptor tyrosine kinase signaling in mammalian eye development.Developmental biology · 2026Review
- Platelet-Rich Plasma in Recurrent Pregnancy Loss: Toward a Precision Medicine Framework for Biologically Guided Patient Selection.Medical sciences (Basel, Switzerland) · 2026Review
- Synthetic Heparan Sulfate-like Oligosaccharides as Tools to Decipher Growth Factor Recognition.Journal of medicinal chemistry · 2026Article
- New perspectives on VEGF signalling in Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2026Review
- Review
- Article
- Apatinib inhibits synovial sarcoma progression and angiogenesis via VEGFR2-mediated AKT/FOXO3A and ERK1/2/FOXM1 signaling pathways.Cell death discovery · 2026Article
- Development of the relationship between tumor and mechanobiology over the past 30 years: a bibliometric analysis.Discover oncology · 2026Article
- 5-HMF inhibits glucocorticoid-induced osteoporosis through the VEGFR2/PI3K/AKT pathway.Scientific reports · 2026Article
- Different types of exercise and myocardial angiogenesis regulation: A scoping review of cardiac-specific evidence in animal models.Physiological reports · 2026Article
- Endothelial USP8 is essential for angiogenesis.Angiogenesis · 2026Article
- Controlling Biogenesis and Engineering of Exosomes to Inhibit Growth and Promote Death in Glioblastoma Multiforme.Brain sciences · 2026Review
408 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular endothelial growth factors (VEGFs) are master regulators of vascular development and of blood and lymphatic vessel function during health and disease in the adult. It is therefore important to understand the mechanism of action of this family of five mammalian ligands, which act through three receptor tyrosine kinases (RTKs). In addition, coreceptors like neuropilins (NRPs) and integrins associate with the ligand/receptor signaling complex and modulate the output. Therapeutics to block several of the VEGF signaling components have been developed with the aim to halt blood vessel formation, angiogenesis, in diseases that involve tissue growth and inflammation, such as cancer. In this review, we outline the current information on VEGF signal transduction in relation to blood and lymphatic vessel biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.